✉news WorldUS Politics first seen 23 h ago, last 11 h ago, peak #3
Sarepta Reports New ELEVIDYS Data at World Muscle Society Congress
Original: Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics presented new findings at the 2026 World Muscle Society Annual Congress showing that ELEVIDYS (delandistrogene moxeparvovec) is safe and delivers clinically meaningful functional benefit in older ambulatory patients with Duchenne muscular dystrophy. The data extend the gene therapy's evidence base beyond younger patient groups, a question that has long been debated by clinicians and regulators in the Duchenne community.
Why now: New clinical data on a leading Duchenne gene therapy is significant for patients, families and investors watching its expanding use.
Sarepta TherapeuticsELEVIDYSWorld Muscle Society
Rank over time, top of the chart is #1. 5 snapshots from 23 h ago to 11 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/489466